Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17372384 | 0.80 | BUB1 (0.58) | BUB1ELANEALDH1A1MEN1TSHR | |
| SCHEMBL1692228 | 0.74 | BUB1 (0.65) | BUB1ELANEGPR119SMN1; SMN2ALDH1A1 | |
| SCHEMBL1003642 | 0.74 | NR1H2 (0.41) | BUB1ELANEGPR119ALDH1A1KDM4E | |
| SCHEMBL2208073 | 0.72 | ELANE (0.62) | BUB1ELANEGPR119HPGDPLK1 | |
| SCHEMBL3445913 | 0.70 | BUB1 (0.60) | BUB1ELANEGPR119SMN1; SMN2ALDH1A1 | |
| SCHEMBL5561169 | 0.69 | KDM4E (0.40) | BUB1ELANEALDH1A1MEN1KMT2A | |
| SCHEMBL23801848 | 0.69 | TP53 (0.49) | ALDH1A1MEN1TSHRKMT2AKDM4E | |
| SCHEMBL30511849 | 0.69 | TP53 (0.49) | ALDH1A1MEN1TSHRKMT2AKDM4E | |
| SCHEMBL22870384 | 0.69 | PLK1 (0.49) | ELANESMN1; SMN2ALDH1A1MEN1PABPC1 | |
| SCHEMBL6341898 | 0.69 | BRD4 (0.46) | BUB1GPR119KDM4ECCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816536-B2 | enantioselective functionalization at the less reactive 4-position; alkenylation of the 4-(leaving group)-6,7-dihydro ring with an electron-withdrawing vinyldiazo compound using a a dirhodium catalyst; drug intermediate | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816536-B2 | enantioselective functionalization at the less reactive 4-position; alkenylation of the 4-(leaving group)-6,7-dihydro ring with an electron-withdrawing vinyldiazo compound using a a dirhodium catalyst; drug intermediate | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816536-B2 | enantioselective functionalization at the less reactive 4-position; alkenylation of the 4-(leaving group)-6,7-dihydro ring with an electron-withdrawing vinyldiazo compound using a a dirhodium catalyst; drug intermediate | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070004787-A1 | enantioselective functionalization at the less reactive 4-position; alkenylation of the 4-(leaving group)-6,7-dihydro ring with an electron-withdrawing vinyldiazo compound using a a dirhodium catalyst; drug intermediate | NATIONAL SCIENCE FOUNDATION | 2007-01-04 | — | — | US | disclosed |
| US-20070004787-A1 | enantioselective functionalization at the less reactive 4-position; alkenylation of the 4-(leaving group)-6,7-dihydro ring with an electron-withdrawing vinyldiazo compound using a a dirhodium catalyst; drug intermediate | NATIONAL SCIENCE FOUNDATION | 2007-01-04 | — | — | US | disclosed |
| US-20070004787-A1 | enantioselective functionalization at the less reactive 4-position; alkenylation of the 4-(leaving group)-6,7-dihydro ring with an electron-withdrawing vinyldiazo compound using a a dirhodium catalyst; drug intermediate | NATIONAL SCIENCE FOUNDATION | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004787-A1 | enantioselective functionalization at the less reactive 4-position; alkenylation of the 4-(leaving group)-6,7-dihydro ring with an electron-withdrawing vinyldiazo compound using a a dirhodium catalyst; drug intermediate | CYP3A4, CYP2D6, CYP3A7 | BUB1 4036/4885ELANE 4062/4885GPR119 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.